Afghanistan vs Europe (WHO region): New cases tested for RR-/MDR-TB
Afghanistan
100.0%
in 2024
Europe (WHO region)
88.0%
in 2024
Afghanistan rank
1st
Europe (WHO region) rank
3rd
New cases tested for RR-/MDR-TB over time
- Afghanistan
- Europe (WHO region)
How they compare
Afghanistan currently reports 100.0% against 88.0% in Europe (WHO region), a difference of 12.0%.
That makes Afghanistan's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 1 time across 13 shared years of data; in 2010 it was Europe (WHO region) ahead.
Afghanistan ranks 1st and Europe (WHO region) ranks 3rd of 192 countries.
Europe (WHO region) has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Europe (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 10.9% | 87.9% | 77.0% | Europe (WHO region) |
| 2020s | 68.8% | 90.8% | 22.0% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher new cases tested for rr-/mdr-tb, Afghanistan or Europe (WHO region)?
- Afghanistan, at 100.0% against 88.0% in Europe (WHO region) as of 2024.
- What is the difference in new cases tested for rr-/mdr-tb between Afghanistan and Europe (WHO region)?
- 12.0%, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Europe (WHO region)?
- 13 years are reported by both, from 2010 to 2024.
- How do Afghanistan and Europe (WHO region) rank globally for new cases tested for rr-/mdr-tb?
- Afghanistan ranks 1st and Europe (WHO region) ranks 3rd of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as New cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.